Bill Meagher's focus with The Deal is on small and microcap equity finance, healthcare and biotechnology, PIPEs, and companies going public. His work has appeared in newspapers and magazines throughout California as well as on PBS, “60 Minutes,” ABC News and CNBC. Meagher has also written video scripts and produced national events for a non-profit educational organization and ghost written two books.
Recent Articles By The Author
Pfizer Hikes Drug Prices Again, Despite President Trump's Promises
While President Trump pledged last month that pharma companies would decide to voluntarily aggress to 'massive' drops in drug prices, clearly nobody told Pfizer.
DEA, DOJ, Making Moves to Contain Opioid Supply Chain
The DOJ made a bust tied to fraud and opioids totaling $2 billion after the FDA held a hearing asking companies like Google and Twitter for help dealing with online opioid sales.
FDA Online Opioid Summit Panelists Praise Open Communication; What's Next?
In 2016, 42,000 Americans died from opioid overdoses. The FDA wants illegal online sales of the drugs halted, and is looking towards tech companies to do some of the lifting.
FDA Will Hold Opioid Summit June 27, Webcast Won't Give Tech Companies Face Time
An FDA summit focusing on how easy it is to score opioids online will mostly be offline keeping companies like Facebook and Google from having to answer questions in a public way.
China Pledges Help With Fentanyl Imports; Says U.S. Must Curb Opioid Demand
Despite a growing trade war between the U.S, and China, drug officials in that country have pledged to try to stop the flow of fentanyl into the U.S.
Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma
Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.
Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus
After Purdue let some of its sales staff go in February, it followed up June 20 by sending the rest of the staff packing.
Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy
The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.
Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers
While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.
Azar Defends Trump Drug Pricing Plan, Faces Doubts From Senate
The health and human services secretary calls for getting rid of rebates between pharmacy benefit managers and drug companies, but senators had plenty of other issues with the Trump administration's blueprint to lower drug prices.